2022-12-08
Editor’s Word: For recommendations on navigating medical health insurance protection within the U.S., go to our medical health insurance sources on Past Sort 1 and Past Sort 2.
On December 8, 2022, Dexcom, an organization that manufactures steady glucose displays (CGMs) for blood sugar administration, introduced the FDA approval for his or her next-generation product, the Dexcom G7 CGM. The G7 is authorised for individuals with all forms of diabetes ages two years and older.
In February of this yr, Dexcom launched medical trial knowledge demonstrating the strongest blood sugar measurement accuracy for any presently authorised CGM. General, CGMs are clinically proven to decrease A1c ranges and enhance blood sugar time in vary, resulting in improved well being outcomes for individuals residing with diabetes.
The G7, cleared as an built-in CGM (iCGM), will be capable of combine with automated insulin supply techniques and might join with wearables just like the Apple Watch and different digital well being apps to assist wearers attain more healthy blood sugar ranges and reduce the burden of illness administration.
The G7 differs in a number of notable methods from the earlier era product, the G6.
The G7 is 60% smaller than the G6, with an all-in-one sensor and transmitter
The nice and cozy-up interval has been reduce down from two hours to half-hour
Now with a 12-hour grace interval to interchange completed sensors for a extra seamless transition between periods
Just like the G6, the G7 doesn’t require finger-stick calibration and sends real-time glucose readings to appropriate units each 5 minutes. The system alerts wearers to predicted low blood sugar ranges earlier than they happen, permitting for therapy to maintain ranges in a wholesome vary.
The product comes with a redesigned cell app, extra customizable excessive and low blood sugar stage alerts and the continued means to share real-time blood sugar ranges with family members and care groups.
In a press launch saying the approval, Kevin Sayer, chairman, president and CEO of Dexcom acknowledged, “There’s a motive Dexcom has the best-selling real-time CGM in the marketplace. For greater than a decade, we’ve pioneered era after era of sensing expertise that persistently delivers improved accuracy, reliability and a less complicated consumer expertise, giving individuals larger management of their diabetes. Once we got down to design G7, our objective was easy: to take advantage of highly effective, easy-to-use CGM out there for individuals with diabetes, whether or not they have kind 1 or kind 2. G7 delivers squarely on that promise. And now that it has been cleared by the FDA, we sit up for making G7 commercially out there within the coming months.”
The G6 will proceed to be out there for the foreseeable future, necessary not solely to these utilizing the G6 with current automated insulin supply techniques but in addition for individuals who have gone via the important strategy of medical health insurance approval to get entry to the product.
Because the G7 turns into out there within the coming months, Dexcom is working with insulin pump corporations, insurers, and different vital gamers to transition the use and integration of the G7.
To be taught extra about Dexcom G7 and for added details about when will probably be out there within the US, go to Dexcom.com/G7.
This content material mentions Dexcom, an energetic accomplice of Past Sort 1.
Information protection by the Past Sort 1 crew is operated independently from any content material partnerships. Past Sort 1 maintains full editorial management of all content material printed on our platforms.